Undifferentiated prostate cancer treated with docetaxel

INTRODUCTION: Undifferentiated prostate cancer is a rare and aggressive disease, and no definitive therapeutic strategy for metastatic undifferentiated prostate cancer has been established. CASE PRESENTATION: We report the case of a 70‐year‐old man with undifferentiated prostate cancer and lymph nod...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Masaki, Yokoyama, Minato, Inoue, Masaharu, Fujii, Yasuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770600/
https://www.ncbi.nlm.nih.gov/pubmed/33392469
http://dx.doi.org/10.1002/iju5.12162
_version_ 1783629542632456192
author Kobayashi, Masaki
Yokoyama, Minato
Inoue, Masaharu
Fujii, Yasuhisa
author_facet Kobayashi, Masaki
Yokoyama, Minato
Inoue, Masaharu
Fujii, Yasuhisa
author_sort Kobayashi, Masaki
collection PubMed
description INTRODUCTION: Undifferentiated prostate cancer is a rare and aggressive disease, and no definitive therapeutic strategy for metastatic undifferentiated prostate cancer has been established. CASE PRESENTATION: We report the case of a 70‐year‐old man with undifferentiated prostate cancer and lymph node metastases. Following the patient’s progression after platinum‐based chemotherapy, we initiated treatment with docetaxel, which resulted in a partial response. The patient was alive for 42 months after initiation of docetaxel, maintaining relatively good quality of life with minimal hospital stay. CONCLUSION: Docetaxel may be a good therapeutic option for metastatic undifferentiated prostate cancer.
format Online
Article
Text
id pubmed-7770600
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77706002020-12-31 Undifferentiated prostate cancer treated with docetaxel Kobayashi, Masaki Yokoyama, Minato Inoue, Masaharu Fujii, Yasuhisa IJU Case Rep Case Reports INTRODUCTION: Undifferentiated prostate cancer is a rare and aggressive disease, and no definitive therapeutic strategy for metastatic undifferentiated prostate cancer has been established. CASE PRESENTATION: We report the case of a 70‐year‐old man with undifferentiated prostate cancer and lymph node metastases. Following the patient’s progression after platinum‐based chemotherapy, we initiated treatment with docetaxel, which resulted in a partial response. The patient was alive for 42 months after initiation of docetaxel, maintaining relatively good quality of life with minimal hospital stay. CONCLUSION: Docetaxel may be a good therapeutic option for metastatic undifferentiated prostate cancer. John Wiley and Sons Inc. 2020-04-20 /pmc/articles/PMC7770600/ /pubmed/33392469 http://dx.doi.org/10.1002/iju5.12162 Text en © 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Kobayashi, Masaki
Yokoyama, Minato
Inoue, Masaharu
Fujii, Yasuhisa
Undifferentiated prostate cancer treated with docetaxel
title Undifferentiated prostate cancer treated with docetaxel
title_full Undifferentiated prostate cancer treated with docetaxel
title_fullStr Undifferentiated prostate cancer treated with docetaxel
title_full_unstemmed Undifferentiated prostate cancer treated with docetaxel
title_short Undifferentiated prostate cancer treated with docetaxel
title_sort undifferentiated prostate cancer treated with docetaxel
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770600/
https://www.ncbi.nlm.nih.gov/pubmed/33392469
http://dx.doi.org/10.1002/iju5.12162
work_keys_str_mv AT kobayashimasaki undifferentiatedprostatecancertreatedwithdocetaxel
AT yokoyamaminato undifferentiatedprostatecancertreatedwithdocetaxel
AT inouemasaharu undifferentiatedprostatecancertreatedwithdocetaxel
AT fujiiyasuhisa undifferentiatedprostatecancertreatedwithdocetaxel

Ejemplares similares